About PolyPid Ltd.
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins.
We developed a long-acting, controlled-release medicine designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. Guided by precision and innovation, PolyPid is redefining how therapies perform and raising the standard of patient care.
2,000+ 2,000+ Patients treated in Clinical trials
60% 60% Reduction in Surgical Sites Infection in Phase lll Clinical Trial
170+ 170+ patients
50+ 50+ days ultra-long release GLP-1 in development
Email Alerts
Alerts are emailed to you whenever certain new company information is posted to this site.